Treatment of Cutaneous Leishmaniasis: Effectiveness, and Adverse Effects of the Drugs

Background: Cutaneous Leishmaniasis is a relatively common disease and cannot be completely controlled. Some reports have suggested drug resistance to the disease and adverse effects of the drug are controversial. The aim of this study was to review different methods of medical treatment, evaluate effects and adverse effects of the drug, and present a protocol for treatment of patients with Cutaneous Leishmaniasis. Materials and Method: In a review method, searching keywords on the Internet, a large number of related articles were extracted. Among them, 66 qualified articles were selected and reviewed. Conclusion: Glucantime is considered to have the most effectiveness and the less adverse effect in patients with Cutaneous Leishmaniasis.

[1]  B. Arana,et al.  Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. , 1990, The American journal of tropical medicine and hygiene.

[2]  S. Sundar,et al.  Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. , 1995, The Journal of infectious diseases.

[3]  J. Chulay,et al.  Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). , 1985, The American journal of tropical medicine and hygiene.

[4]  A. Bryceson,et al.  High-dose sodium stibogluconate treatment of cutaneous leishmaniasis in Kenya. , 1983, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[5]  J. Berman,et al.  Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. , 1998, Bulletin of the World Health Organization.

[6]  Marr Jj.  Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis. , 1991 .

[7]  A. Bryceson,et al.  A double-blind clinical trial of the treatment of cutaneous leishmaniasis with paromomycin ointment. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[8]  J. Berman.  Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  G. S. Nabors,et al.  Activity of pentostam (sodium stibogluconate) against cutaneous leishmaniasis in mice treated with neutralizing anti-interferon-gamma antibody. , 1995, The American journal of tropical medicine and hygiene.

[10]  M. Gramiccia,et al.  Treatment of visceral leishmaniasis in children with liposomal amphotericin B. , 1997, The Journal of pediatrics.

[11]  S. Norton,et al.  Cutaneous leishmaniasis acquired during military service in the Middle East. , 1992, Archives of dermatology.

[12]  A. Bryceson.  DIFFUSE CUTANEOUS LEISHMANIASIS IN ETHIOPIA , 1970 .

[13]  R. Reithinger.  Control of leishmaniasis. , 1999, The Veterinary record.

[14]  U. Biswas,et al.  Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar , 1994, The Lancet.

[15]  R. Balaña-Fouce,et al.  Effects of cationic diamidines on polyamine metabolism in the trypanosomatid Crithidia fasciculata. , 1996, Life sciences.

[16]  P. Olliaro,et al.  Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[17]  J. Soto,et al.  Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. , 1994, The American journal of tropical medicine and hygiene.

[18]  Contribution to the Progress of Antimony Therapy of Kala-Azar. , 1937 .

[19]  R. Balaña-Fouce,et al.  Effects of cationic diamidines on polyamine content and uptake on Leishmania infantum in in vitro cultures. , 1996, Biochemical pharmacology.

[20]  Y. Dowlati.  Treatment of cutaneous leishmaniasis (Old World). , 1996, Clinics in dermatology.

[21]  J. Berman,et al.  Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. , 1992, The American journal of tropical medicine and hygiene.

[22]  G. Kirigi,et al.  Is one year follow-up justified in kala-azar post-treatment? , 1994, East African medical journal.

[23]  P. Olliaro,et al.  A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. , 1995, The American journal of tropical medicine and hygiene.

[24]  J. Berman.  Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. , 1988, Reviews of infectious diseases.

[25]  S. Halevy,et al.  Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. , 1992, Journal of the American Academy of Dermatology.

[26]  S. Reed,et al.  Cytokines in the treatment of leishmaniasis: From studies of immunopathology to patient therapy , 1994, Biotherapy.